RET and renal cell carcinoma: Sunitinib, targeting VEGFR1-3, PDGFR-α/β, KIT, FLT-3, colony-stimulating factor receptor Type 1 (CSF-1R), RET, for gastrointestinal stromal and pancreatic cancers and renal cell carcinoma.